Chronic obstructive pulmonary disease (COPD) is a complex and progressive respiratory disease characterized by incompletely reversible bronchial obstruction. The effects of current therapeutic options in early stages of COPD have been poorly investigated in the past, being this specific topic revamped by the results of recent secondary analyses from large international trials. Aim: to measure and monitor in real life the changes in main clinical outcomes and health care resources in patients suffering from mild-to-moderate and severe COPD treated with only tiotropium br. for twenty-four months. Methods: the population sample of the present observational retrospective study consists in 319 COPD subjects (214 males; average age 71.7years±06se) automatically extracted from the Data Base of the Health Care Institution. Inclusion criteria were: age ≥ 40y; basal FEV1 <80% predicted and FEV1/FVC <70%; regular treatment with only 18mcg tiotropium br. for the following two years). All subjects were divided into two subsets according to their FEV1 basal value: Group 1 ≤50%, and Group B >50% predicted). Lung function; n. exacerbations; n. hospitalizations; absenteeism; n. GP's visits, and use of systemic steroids or antibiotics were checked during the observational period and mean values compared in both subsets with those of the twelve months M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 3 preceding tiotropium br. (such as during other therapeutic strategies
Only since when the analyses of data from the two most important international clinical trials carried out in the last years have become available ( 3,4 ), researchers have begun to accept and support the hypothesis that also the earlier treatment of COPD might be useful and convenient ( 5-9 ). To note that this interesting suggestion comes only from post-hoc and secondary analyses of these large studies, which were originally designed for other primary end-points, still being such evidence not confirmed in real life on the basis of studies specifically designed.
The aim of the present study was to measure the changes in lung function; main clinical outcomes, and health care resources achievable in
patients suffering from severe and from mild-to-moderate COPD ( 1 ) both treated with only tiotropium 18 mcg daily for two years.
Materials and Methods
The population sample was extracted automatically from the Data Base of our Institution which contains files related to more than 52,000 subjects suffering from respiratory diseases. Variables to be extracted from the "1st visit" file of all subjects who met the preliminary entry criteria were the following: :
• gender;
• age;
• smoking status;
• baseline pulmonary function (FEV1% pred. and FEV1/FVC %);
• symptoms claimed;
• annual number of hospital admissions; their duration; number of GP visits; number of exacerbations and number of days of inactivity;
• daily home therapy (only pharmacological classes).
During the second selection phase, the additional criteria that had to be met were: the presence in the DataBase of data from visits and In mild-to-moderate COPD a significant and remarkable increase of lung function (p<0.001) was seen, together with a significant drop in n.
hospitalizations and their duration (p<0.001 and p<0.002, respectively); n.
exacerbations (p<0.003); n. GP's visits (p<0.001), and n. days of inactivity (p<0.001), while the n. courses of both antibiotics and systemic steroids did not change significantly (p=ns) (tab. 3).
Discussion
Data from the present retrospective investigation lead to several considerations of some interest.
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13 First of all, when patients with COPD refers to a Specialist Centre for the first time, usually their disease had already had a clinical and a pharmaco-economic impact, which proves to be absolutely relevant, independently of their spirometrical severity. In particular, subjects with a mild-to-moderate disease showed an unexpectedly remarkable impact.
Secondly, the overall therapeutic approach confirmed once again basically insufficient.
Actually, the alarming evidence emerging is that COPD still is not properly managed within the community and that the home therapy (which is based on systemic steroids) is frequently not related to the true impact of the disease, thus still mirroring a generic and non specific approach to these patients. Actually, the home therapy followed over the last 12 months before the first visit to the Centre (such as in the period year -1 vs
year 0 values) did not produce any significant improvement of clinical and pharmaco-economic variables independently of the severity of spirometric findings.
The switch to tiotropium 18mcg monotherapy on a regular basis The present retrospective survey had been mainly designed with the specific aim to investigate in real life the opportunity and the convenience of an earlier intervention in COPD. Actually, when an appropriate, and long-term treatment on a regular daily base was given to subjects with mild-to-moderate COPD, no decline in pulmonary function was assessed in the following two years, and an average recovery in lung function of more than 13% was observed over 24 months. This evidence tends to support and emphasize both the utility and the convenience of the earlier treatment in COPD, i.e. starting when the functional (and presumably also the biological) damage is lower, and consequently the room for airway recovery is presumed to be larger ( 
